- Home
- PII vs AKRO Comparison
PII vs AKRO Comparison
Compare PII & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PII
- AKRO
- Stock Information
- Founded
- PII 1954
- AKRO 2017
- Country
- PII United States
- AKRO United States
- Employees
- PII N/A
- AKRO N/A
- Industry
- PII Recreational Games/Products/Toys
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PII Consumer Discretionary
- AKRO Health Care
- Exchange
- PII Nasdaq
- AKRO Nasdaq
- Market Cap
- PII 3.6B
- AKRO 3.7B
- IPO Year
- PII 1987
- AKRO 2019
- Fundamental
- Price
- PII $61.58
- AKRO $53.95
- Analyst Decision
- PII Hold
- AKRO Buy
- Analyst Count
- PII 11
- AKRO 10
- Target Price
- PII $49.10
- AKRO $73.56
- AVG Volume (30 Days)
- PII 1.2M
- AKRO 3.5M
- Earning Date
- PII 10-28-2025
- AKRO 11-07-2025
- Dividend Yield
- PII 4.76%
- AKRO N/A
- EPS Growth
- PII N/A
- AKRO N/A
- EPS
- PII N/A
- AKRO N/A
- Revenue
- PII $6,961,400,000.00
- AKRO N/A
- Revenue This Year
- PII N/A
- AKRO N/A
- Revenue Next Year
- PII $4.46
- AKRO N/A
- P/E Ratio
- PII N/A
- AKRO N/A
- Revenue Growth
- PII N/A
- AKRO N/A
- 52 Week Low
- PII $30.92
- AKRO $21.34
- 52 Week High
- PII $84.08
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PII 53.96
- AKRO 71.42
- Support Level
- PII $55.71
- AKRO $45.20
- Resistance Level
- PII $64.96
- AKRO $54.53
- Average True Range (ATR)
- PII 2.40
- AKRO 1.16
- MACD
- PII -0.22
- AKRO 0.96
- Stochastic Oscillator
- PII 58.36
- AKRO 93.89
About PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.